RemeGen Ltd.

Despite struggling with the financial burden, Chinese firm RemeGen is pulling out all the stops for its ongoing global Phase III RemeMG study to repeat the positive safety and efficacy outcomes from

Throughout 2024 and against persistent financial headwinds, novice and returning sole Chinese company sponsors of clinical trials initiated a total of seven new global Phase III programs that included

Many of China’s homegrown first-in-class drugs have had a hard time becoming rainmakers for their originators, with few becoming blockbusters in domestic or international sales terms. Since the first

BioNTech’s close to $1bn acquisition of Biotheus announced earlier this month marked another big M&A deal between a Chinese biotech and a foreign firm following AstraZeneca’s roughly $1.2bn buyou